Patient community and AI mentor
Belong.Life
BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Mixed 7 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Belong.Life BelongAI Dave AI cancer mentor (consumer app and community); enterprise private-label, pharma and clinical tools not assessed
Astra review conflicted: OpenAI model in role record.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | provide automated AI-generated responsesSource AI Mentor Terms of Service. The service is named 'Dave the AI Cancer Mentor'. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Belongtail Ltd (Israeli company) is named as data controller. How-it-works page says 'proprietary conversational AI technology' and 'LLM (large language model engines)' with no model maker named. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | allow Users to ask free text questions in certain health-related fieldsSource Patient downloads or registers and asks questions. Mentor can nudge users (see question 4). Muting notifications is allowed. |
| 4. Patient sets the task | No | documented Not independently replicated | the Service may be able to initiate and encourage further conversation with the User to increase engagementSource Judgment call. Patient asks free-text questions, but the Terms document operator-initiated engagement prompts, and the operator sells pharma and advertiser access (Belong enterprise pages). |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | allow Users to ask free text questions in certain health-related fieldsSource Self-started rule applied (cites question 3 source). Terms: notifications can be stopped by muting the channel. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | provide automated AI-generated responsesSource Patient reads the AI's answers directly. |
| 7. Patient can correct or challenge | Yes | documented Not independently replicated | Users can provide feedback on the relevance and helpfulness of the answersSource Weak yes. Feedback route only. Terms say Belongtail is 'not under any obligation' to use human review of AI content. |
| 8. Patient can get a copy | Yes | documented Not independently replicated | we can provide you all your Personal Information which you provided to us in a structured, commonly used and machine-readable formatSource Request by contacting Belongtail. |
| 9. Patient can delete | Yes | documented Not independently replicated | deleting your Account from the Service, in which case we will delete any such Personal Information pursuant to any applicable privacy lawsSource Policy also allows retention for legal needs and depersonalized activity history. |
| 10. Training or sale does not override patient choice | No | documented Not independently replicated | in order to train our AI models, improve our Services, and create new ServicesSource Terms: Belongtail 'may use the Content of your conversations' for this. How-it-works says the AI was trained on user data. No opt-out documented. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted only. Terms limit use to a personal, non-commercial license. |
| 12. No advertising or data business | No | documented Not independently replicated | In those groups you may see advertisements which relate to your type of disease or type of groups.Source Privacy: ads shown in groups. Belong enterprise pages sell 'Media for Advertisers' and pharma reach. Privacy also allows sharing aggregated data with third parties for research. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Mixed
Legacy editorial placement, pre-method: 69
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 69
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 69. Not comparable with v1.3 positions.
Mixed
BelongAI Dave offers patient cancer questions, information, and document sharing. Its policy also permits commercial content and secondary use of depersonalized history. The posture is Mixed, with consumer and enterprise deployments assessed separately.
Patient agency
How this tool changes agency
Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.
Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified
Patient agency assessment
Who sets and changes the goal?
Patients can ask their own questions and choose document sharing in the described consumer workflow. Sponsor-content mechanisms create additional objectives, but actual steering of clinical recommendations was not established.
What can the patient understand, question, or do?
Cancer information, community experience and a shareable binder can broaden patient questions. Per-answer citations, correction of mentor interpretations and moderation appeals were not verified.
Can the patient evaluate the conditions of use?
The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.
Text findings
Conditions of use
Published controls and their limits
The seed's general positive label needs the documented commercial and secondary-use conditions. Account deletion is not a promise to remove every depersonalized derivative.
What remains unknown?
Not tested or not established
Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
- https://belong.life/belong-ai-cancer-mentor-app/
- https://belong.life/privacy-policy/
- https://belong.life/
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Sponsor visibility, mentor source provenance, redirection and correction behavior remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Moderate for public product and policy claims, limited for actual patient experience (AI-assisted draft)